Lazard Asset Management
LCTX icon

Lazard Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Lazard Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-148
Closed – – 2444
2024
Q4 		$0 Hold
148
– – ﹤0.01% 2417
2024
Q3 		$0 Sell
148
-255
-63% -$236 ﹤0.01% 2371
2024
Q2 		$0 Sell
403
-5,656
-93% -$6.25K ﹤0.01% 2344
2024
Q1 		$8K Sell
6,059
-3,356
-36% -$3.81K ﹤0.01% 1882
2023
Q4 		$10K Buy
9,415
+578
+7% +$633 ﹤0.01% 2097
2023
Q3 		$10K Buy
8,837
+457
+5% +$622 ﹤0.01% 2143
2023
Q2 		$11K Buy
8,380
+314
+4% +$434 ﹤0.01% 2176
2023
Q1 		$11K Sell
8,066
-76,575
-90% -$107K ﹤0.01% 2119
2022
Q4 		$98K Buy
84,641
+6,667
+9% +$8.4K ﹤0.01% 1543
2022
Q3 		$88K Buy
+77,974
New +$114K ﹤0.01% 1519
2022
Q1 		– Sell
-21,610
Closed -$52K – 2434
2021
Q4 		$52K Buy
+21,610
New +$50.6K ﹤0.01% 1723

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Lazard Asset Management's LCTX Position: Q1 2025 in Review

Lazard Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q1 2025, closing a stake of 148 shares.

Lazard Asset Management first reported a position in LCTX in Q4 2021 and held it in 11 quarters. The position peaked at $98K in Q4 2022. 127 funds tracked by Wall St. Rank hold LCTX as of Q1 2025.

  • Lazard Asset Management reported no remaining Lineage Cell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lazard Asset Management sold 148 Lineage Cell Therapeutics shares in Q1 2025.
  • Lazard Asset Management first reported a position in Lineage Cell Therapeutics in Q4 2021 and held it in 11 quarters.
  • Lazard Asset Management's Lineage Cell Therapeutics position peaked at $98K in Q4 2022.
  • 127 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2025.

Based on Lazard Asset Management's 13F filing for Q1 2025, filed 15 May 2025.